Results 241 to 250 of about 133,537 (299)

Calycosin Targets the CYP1B1‐AKT/SP1‐GPX4 Axis to Modulate Ferroptosis in Colorectal Carcinogenesis

open access: yesPhytotherapy Research, Volume 40, Issue 2, Page 721-736, February 2026.
Mechanism of Calycosin in Regulating Ferroptosis in Colorectal Cancer via Binding to CYP1B1. ABSTRACT Calycosin, a natural flavonoid small‐molecule compound derived from traditional Chinese medicine, has demonstrated remarkable pharmacological activity in the field of cancer therapy.
Lihan Bie   +9 more
wiley   +1 more source

Adaptive Seamless Phase II/III Randomization Test Considering Treatment Group Selection Based on Short–Term Binary Outcomes

open access: yesStatistics in Medicine, Volume 45, Issue 3-5, February 2026.
ABSTRACT Recently, adaptive seamless phase II/III designs (ASDs) have gained attention because they improve the efficiency of drug development. In an ASD, a phase II trial, which explores the dose–response relationships and identifies treatments for the phase III trial, is combined with a phase III trial, which aims to demonstrate the efficacy and ...
Funato Sato   +4 more
wiley   +1 more source

Tertiary lymphoid structures: Defining immune subtypes and enabling precision immunotherapy in nasopharyngeal carcinoma

open access: yes
Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Fan Liu, Lei Xiong, Xia Yu, Mingfang Ji
wiley   +1 more source

RCC1 Domain‐Containing Protein 1 Promotes Colon Cancer Malignant Progression by Activating Autophagy‐Dependent WNT5A Secretion in Cancer‐Associated Fibroblasts

open access: yesJournal of the Royal Society of New Zealand, Volume 56, Issue 1, February 2026.
RCCD1 is upregulated in colon cancer and cancer‐associated fibroblasts (CAFs). In CAFs, RCCD1 overexpression activates AMPK/mTOR/ULK1 signaling, enhancing autophagy. This stimulates autophagic secretion of WNT5A. WNT5A then activates the nonclassical Wnt/CaMKII/ERK pathway in tumor cells, promoting epithelial‐mesenchymal transition (EMT), proliferation,
Chao Liu   +3 more
wiley   +1 more source

Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Little is known about the genetic background of individuals with familial pancreatic cancer (PC). Integrating germline testing into surveillance may uncover previously unrecognized hereditary susceptibility and expand prevention strategies beyond BRCA testing alone. This study evaluated the genetic landscape of high‐risk individuals
Salvatore Paiella   +33 more
wiley   +1 more source

Blurring the Lines: Co‐Occurrence of MSH6 Variant and MLH1 Constitutional Epimutation in a Young Colorectal Cancer Patient

open access: yesClinical Genetics, Volume 109, Issue 2, Page 363-367, February 2026.
We report a unique case of early‐onset colorectal cancer with both a germline MSH6 variant and constitutional mosaic MLH1 epimutation, revealing a possible digenic mechanism underlying Lynch syndrome. This case highlights the diagnostic complexity of mismatch repair deficiency and the value of integrative tumor–germline molecular profiling.
Aasem Abu Shtaya   +7 more
wiley   +1 more source

Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Oxaliplatin‐induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem. Previous basic studies have suggested that the dipeptidyl peptidase‐4 (DPP‐4) inhibitor alogliptin may prevent OIPN.
Yusuke Koura   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy